Read by QxMD icon Read

Alopecia chemotherapy

Young-Cheol Lim, Hyeongi Kim, Sang Moo Lim, Jin Su Kim
BACKGROUND: Chemotherapy-induced alopecia has been well documented as a cause of distress to patients undergoing cancer treatment. Almost all traditional chemotherapeutic agents cause severe alopecia. Despite advances in the treatment of chemotherapy-induced alopecia, there is no effective treatment for preventing chemotherapy-induced alopecia. METHODS: In the present study, we investigated the potential role of a multi-target iron chelator, M30 in protecting against cyclophosphamide-induced alopecia in C57BL/6 mice implanted with an osmotic pump...
February 13, 2019: BMC Cancer
Luis Manso, Fernando Moreno Antón, Yann Izarzugaza Perón, Juan I Delgado Mingorance, Pablo Borrega García, María J Echarri González, Noelia Martínez-Jañez, Ana López-González, Clara Olier Garate, Anabel Ballesteros García, Ignacio Chacón López-Muñíz, Eva Ciruelos Gil, Jose Angel García-Sáenz, Luis Paz-Ares
Eribulin is active and safe in heavily pre-treated metastatic breast cancer patients. Few safety data have been published in third line. We aimed to report the specific safety profile on third line beyond taxanes and anthracyclines in advanced breast cancer (ABC). A multicenter phase II, prospective study was conducted in anthracyclines and taxanes pre-treated HER2-negative ABC, programmed to receive eribulin as third-line chemotherapy. Adverse events (AEs) were assessed and classified according to CTCAE. In addition, efficacy, in terms of overall survival (OS) and progression-free survival (PFS), and the dynamics of circulating tumor cells (CTCs) during treatment were assessed...
February 8, 2019: Breast Journal
Vanesa Ortega, Antonio Antón, Isabel Garau, Noemia Afonso, Lourdes Calvo, Yolanda Fernández, María Martínez-García, Esperanza Blanco, Pilar Zamora, Mirta García, José Juan Illarramendi, César Augusto Rodríguez Sánchez, Miguel Sampayo, Elena Aguirre, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac
BACKGROUND: Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI) and previous use of taxanes in the neoadjuvant or adjuvant setting have been associated with worse outcomes for patients receiving first-line chemotherapy for HER2-negative MBC. The aim of the present trial was to evaluate the efficacy and safety of eribulin as first-line therapy for patients with HER2-negative MBC with these poor prognostic factors...
December 20, 2018: Clinical Breast Cancer
Omar Abdel-Rahman
PURPOSE: To evaluate the impact of sex on toxicity and efficacy outcomes among patients with metastatic colorectal cancer receiving first-line 5-fluorouracil-based regimens. PATIENTS AND METHODS: A pooled analysis of data sets from 5 clinical trials (NCT00115765, NCT00364013, NCT00272051, NCT00305188, NCT00384176) was performed. Kaplan-Meier analysis and log-rank testing were used to assess the differences in overall and progression-free survival between male and female subjects...
December 28, 2018: Clinical Colorectal Cancer
Jacqueline Guidry, Mariah Brown, Theresa Medina
Immune checkpoint modulators are becoming more prevalent in clinical use for the treatment of metastatic melanoma and other malignancies. These drugs, including programmed death 1 (PD-1) inhibitors, have a high incidence of immune adverse events, including cutaneous manifestations. Alopecia is a known side effect with these drugs, but previous reports describe chemotherapy-induced alopecia. We report a case of alopecia areata in a patient on monotherapy with pembrolizumab (PD-1 inhibitor). It is important for the dermatologist to recognize and appropriately treat to decrease morbidity for these patients...
December 15, 2018: Dermatology Online Journal
Pramod Kumar Sharma, Arup Kumar Misra, Ajay Gupta, Surjit Singh, Puneet Dhamija, Puneet Pareek
INTRODUCTION: Adverse drug reaction (ADR) is a public health problem which constitutes one of the leading causes of morbidity and mortality worldwide. In India, only a few studies reported cancer chemotherapy-induced ADRs. The objectives of the present study were to assess the organ system involved, frequency, severity, and preventability of the ADRs occurred. MATERIALS AND METHODS: Data on ADRs of retrospective cohorts were extracted from the filled ADR forms received from the department of radiation oncology...
September 2018: Indian Journal of Pharmacology
Daniela Luethy, Angela E Frimberger, Daniela Bedenice, Barbara S Byrne, Erin S Groover, Rachel B Gardner, Trisha Lewis, Valerie S MacDonald, Lauren Proctor-Brown, Joy E Tomlinson, Kenneth M Rassnick, Amy L Johnson
BACKGROUND: Prognosis associated with lymphoma in horses is poorly characterized, and treatment is often palliative. Long-term outcome after chemotherapy for horses with lymphoma is not well documented. OBJECTIVE: To report long-term outcome of horses with lymphoma treated with chemotherapy. ANIMALS: Fifteen equids. METHODS: Retrospective case series. Medical record search and call for cases on the ACVIM listserv for horses treated with chemotherapy for lymphoma...
January 12, 2019: Journal of Veterinary Internal Medicine
Marniza Saad, Flora Li Tze Chong, Anita Zarina Bustam, Gwo Fuang Ho, Rozita Abdul Malik, Wan Zamaniah Wan Ishak, Vincent Chee Ee Phua, Mastura Md Yusof, Ning Yi Yap, Adlinda Alip
BACKGROUND: Scalp cooling has been shown in several studies to be an effective method in preventing chemotherapy-induced alopecia (CIA). Data on the use of scalp cooling in Asian countries are limited, and evidence for its use and efficacy among our patients are not available. OBJECTIVE: The aim of this study was to assess the effectiveness and tolerability of scalp cooling among breast cancer patients in our study population. METHODS: Consecutive breast cancer patients receiving FE75 C, FE100 C, FE100 C-D, docetaxel75 or docetaxel, and cyclophosphamide (TC) at our treatment center were recruited and allocated to the treatment (scalp cooling, DigniCapTM system) or control group in this prospective nonrandomized controlled study...
April 2018: Indian Journal of Cancer
Jenna R Stoehr, Jennifer N Choi, Maria Colavincenzo, Stefan Vanderweil
Topical minoxidil is a well-known and often-utilized drug in dermatological practice for the treatment of alopecia. It was approved by the United States Food and Drug Administration for the treatment of androgenetic alopecia in 1988. Since its approval, minoxidil has been used off-label for the treatment of many other types of alopecia, with minimal formal evidence of efficacy. Conditions for which the use of topical minoxidil has been reported include telogen effluvium, alopecia areata (AA), scarring alopecia, eyebrow hypotrichosis, monilethrix, and chemotherapy-induced alopecia (CIA)...
January 2, 2019: American Journal of Clinical Dermatology
Georg-Peter Breitbach, Panagiotis Sklavounos, Christian Veith, Serban-Dan Costa, Walther Kuhn, Erich-Franz Solomayer, Ingolf Juhasz-Boess, Clemens Tempfer
BACKGROUND AND PURPOSE: Choriocarcinoma (CCA) is a rare form of malignant trophoblastic disease. Systemic polychemotherapy with etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine (EMA/CO) is the mainstay of treatment for metastatic disease. Due to the rarity of the condition, however, the evidence basis for this management is small and other chemotherapy regimens may also be effective. The reported case presents anecdotal evidence of an effective etoposide monotherapy treatment...
December 19, 2018: Archives of Gynecology and Obstetrics
Lynn J Howie, Nancy S Scher, Laleh Amiri-Kordestani, Lijun Zhang, Bellinda L King-Kallimanis, Yasmin Choudhry, Jason Schroeder, Kirsten B Goldberg, Paul G Kluetz, Amna Ibrahim, Rajeshwari Sridhara, Gideon M Blumenthal, Richard Pazdur, Julia A Beaver
On December 20, 2017, the Food and Drug Administration granted regular approval to pertuzumab in combination with trastuzumab and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) at high risk of recurrence. Approval was based on data from the APHINITY trial, which randomized patients to receive pertuzumab or placebo in combination with trastuzumab and chemotherapy. After 45.4 months median follow-up, the proportion of invasive disease-free survival (IDFS) events in the intent-to-treat population was 7...
December 14, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Ivan Baltadzhiev, Nedialka Popivanova
OBJECTIVE: To report a rare case of maculopapular rash on the scalp in a patient with Mediterranean spotted fever (MSF). CLINICAL PRESENTATION AND INTERVENTION: A 58-year-old woman with breast cancer and chemotherapy-induced alopecia contracted MSF. Her clinical features were typical, except for a maculopapular rash covering the scalp. The diagnosis of MSF was confirmed by the immunofluorescent assay. The disease had a favorable course and the patient was discharged in a good condition...
December 3, 2018: Medical Principles and Practice: International Journal of the Kuwait University, Health Science Centre
Gennaro Riccio, Eduardo Sommella, Nadia Badolati, Emanuela Salviati, Sara Bottone, Pietro Campiglia, Monica Dentice, Gian Carlo Tenore, Mariano Stornaiuolo, Ettore Novellino
Chemotherapy-induced alopecia (CIA) is a common side effect of conventional chemotherapy and represents a major problem in clinical oncology. Even months after the end of chemotherapy, many cancer patients complain of hair loss, a condition that is psychologically difficult to manage. CIA disturbs social and sexual interactions and causes anxiety and depression. Synthetic drugs protecting from CIA and endowed with hair growth stimulatory properties are prescribed with caution by oncologists. Hormones, growth factors, morphogens could unwontedly protect tumour cells or induce cancer cell proliferation and are thus considered incompatible with many chemotherapy regimens...
November 20, 2018: Nutrients
Tiziana Prochilo, Alessandra Huscher, Federica Andreis, Mara Mirandola, Elisabetta Zaina, Barbara Pomentale, Chiara Pedrali, Laura Zanotti, Stefano Mutti, Alberto Zaniboni
BACKGROUND: The most effective agents in the treatment of breast cancer have as common side effect the hair loss. Some studies reported a reduction of hair loss with the use of the scalp cooling device. Indeed, it decreases the drug accumulation in the hair follicles. We report our preliminary experience with a scalp cooling device in reducing chemotherapy-induced alopecia and related distress in breast cancer patients undergoing adjuvant chemotherapy. METHODS: Hair loss grading and treatment tolerability were evaluated during chemotherapy every 21 days and 3 weeks after the last cycle of chemotherapy via Dean's scale by patients and operators and a comfort analogic scale by patients...
November 19, 2018: Reviews on Recent Clinical Trials
Shirish M Gadgeel, James P Stevenson, Corey J Langer, Leena Gandhi, Hossein Borghaei, Amita Patnaik, Liza C Villaruz, Matthew Gubens, Ralph Hauke, James Chih-Hsin Yang, Lecia V Sequist, Robert Bachman, Sanatan Saraf, Harry Raftopoulos, Vassiliki Papadimitrakopoulou
OBJECTIVES: Platinum-based chemotherapy for advanced non-small-cell lung cancer (NSCLC) has modest benefit overall, but has the potential to amplify immune responses. In cohorts A-C of the multicohort phase 1/2 study KEYNOTE-021 (, NCT02039674), we evaluated combinations of platinum-doublet chemotherapy with the anti-programmed death 1 monocloncal antibody pembrolizumab. MATERIALS AND METHODS: Patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations were randomized to pembrolizumab 2 or 10 mg/kg Q3W plus carboplatin area under the serum concentration-time curve (AUC) 6 mg/mL/min plus paclitaxel 200 mg/m2 (cohort A, any histology), carboplatin AUC 6 mg/mL/min plus paclitaxel 200 mg/m2 plus bevacizumab 15 mg/kg (cohort B, non-squamous), or carboplatin AUC 5 mg/mL/min plus pemetrexed 500 mg/m2 (cohort C, non-squamous) for 4 cycles followed by maintenance pembrolizumab (cohort A), pembrolizumab plus bevacizumab (cohort B), or pembrolizumab plus pemetrexed (cohort C)...
November 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Maria Monica Haydock, Saroj Sigdel, Toni Pacioles
Since its emergence as a chemotherapy agent, gemcitabine has been associated with cutaneous adverse reactions. Rash is reported to be the most common cutaneous adverse effect. Other reported cutaneous reactions in the literature include bullous dermatosis, pseudocellulitis, subacute cutaneous lupus alopecia, and palmar-plantar erythrodysesthesia. Skin necrosis is a very rare adverse effect of this otherwise well-tolerated chemotherapeutic agent. In searching the literature, only one other case has been reported...
2018: SAGE Open Medical Case Reports
Dustin H Marks, Azam Qureshi, Adam Friedman
Importance: Chemotherapy-induced alopecia as well as nail and cutaneous changes occur in up to 89% of patients receiving taxane-based chemotherapy and are associated with cosmetic concerns, psychosocial distress, and overall morbidity. Objective: To review the efficacy and safety of interventions to prevent taxane-induced dermatologic adverse events. Evidence Review: PubMed and Scopus databases were systematically reviewed for studies published in the English language from January 1, 1980, to August 13, 2018...
October 31, 2018: JAMA Dermatology
Mario Lacouture, Vincent Sibaud
Targeted therapies and immunotherapies are associated with a wide range of dermatologic adverse events (dAEs) resulting from common signaling pathways involved in malignant behavior and normal homeostatic functions of the epidermis and dermis. Dermatologic toxicities include damage to the skin, oral mucosa, hair, and nails. Acneiform rash is the most common dAE, observed in 25-85% of patients treated by epidermal growth factor receptor and mitogen-activated protein kinase kinase inhibitors. BRAF inhibitors mostly induce secondary skin tumors, squamous cell carcinoma and keratoacanthomas, changes in pre-existing pigmented lesions, as well as hand-foot skin reactions and maculopapular hypersensitivity-like rash...
October 30, 2018: American Journal of Clinical Dermatology
Hikmat Permana, Guntur Darmawan, Ervita Ritonga, Maya Kusumawati, Miftahurachman Miftahurachman, Nanny Natalia Soetedjo
Adrenocortical carcinoma (ACC) is a rare solid tumor with an incidence of 0.5 to 2 cases per million per year. It affects women more commonly than men with a ratio of 1.5:1. Ectopic ACC are considered to be extremely rare with no exact incidence data yet. We report an interesting case of hepatic ACC in a young woman with clinical signs of virilization.A-21-year old Sundanese woman visited our endocrine clinic with progressive hirsutism over the face, body, and extremities starting 14 years previously. She had irregular, heavy periods when she was 7 years old...
July 2018: Acta Medica Indonesiana
Tyler Werbel, Philip R Cohen
Taxane chemotherapy and adjuvant endocrine therapy are commonly used in breast cancer patients following surgery. We describe a 59-year-old woman with a triple-positive invasive right breast cancer that was treated with surgery, radiation, chemotherapy, and adjuvant hormonal therapy. She subsequently developed scalp alopecia, with histopathological features of both androgenetic alopecia and alopecia areata; the hair loss did not resolve after completion of her chemotherapy. Significant clinical improvement was observed with topical minoxidil therapy...
July 27, 2018: Curēus
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"